Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $123.33 Consensus Target Price from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned an average rating of “Hold” from the twenty research firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $123.33.

ZBH has been the subject of a number of recent research reports. Royal Bank of Canada boosted their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, November 4th. Raymond James decreased their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Oppenheimer dropped their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 15th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Finally, Wells Fargo & Company raised their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st.

Zimmer Biomet Price Performance

Shares of ZBH opened at $104.47 on Friday. The stock has a market cap of $20.80 billion, a P/E ratio of 19.86, a P/E/G ratio of 1.96 and a beta of 1.02. The business’s fifty day moving average is $108.03 and its 200 day moving average is $108.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet has a 12-month low of $100.67 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period last year, the firm earned $1.65 earnings per share. Sell-side analysts anticipate that Zimmer Biomet will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZBH. Larson Financial Group LLC lifted its stake in shares of Zimmer Biomet by 125.4% during the 2nd quarter. Larson Financial Group LLC now owns 2,105 shares of the medical equipment provider’s stock valued at $228,000 after buying an additional 1,171 shares in the last quarter. National Bank of Canada FI lifted its position in shares of Zimmer Biomet by 12.7% during the second quarter. National Bank of Canada FI now owns 115,693 shares of the medical equipment provider’s stock worth $12,258,000 after acquiring an additional 13,055 shares in the last quarter. Foundry Partners LLC bought a new position in shares of Zimmer Biomet in the second quarter worth $568,000. Private Advisor Group LLC grew its position in shares of Zimmer Biomet by 10.8% in the second quarter. Private Advisor Group LLC now owns 12,022 shares of the medical equipment provider’s stock valued at $1,305,000 after purchasing an additional 1,176 shares in the last quarter. Finally, Strategic Financial Concepts LLC bought a new stake in shares of Zimmer Biomet during the 2nd quarter valued at $1,563,000. 88.89% of the stock is currently owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.